Longwood Fund
Venture capitalBoston · Seed–Series B · 50 people tracked
Also known as LONGWOOD MANAGEMENT LLC
Investment thesis
Longwood Fund focuses on creating and investing in novel healthcare and biotech companies that develop important treatments for patients. The firm acts as company co-founders and value-add investors, partnering with entrepreneurs, scientists, and academic innovators to turn groundbreaking discoveries into companies. It leverages its own company creation and operating experience to build businesses that both benefit patients and generate significant investor value. Its partners have founded over 20 biotech companies, which have launched roughly 25 drugs.
Source: firm website, verified Aug 3, 2026.
Team · 50 people
from the firm's website & public directories
What they invest in
from 26 of 74 portfolio companiesBiotech ×20Medical Devices ×11Healthtech ×10AI & Machine Learning ×4Digital Health ×2Deep Tech ×1
HQs:United States×23Canada×1
Investments · 74 tracked
founders shown can be your intro pathBiotechCambridge, US
RICHARD YOUNG(Director)MICHAEL HIGGINS(Director)JORGE CONDE(Director)JOSH MANDEL-BREHM(Executive Officer, Director)
BoardAMIR NASHAT(Director)
Board seatShaan C. Gandhi· per SEC Form D · filed Oct 2021
BiotechBoston, US
Lea Hachigian(Director)David Southwell(Executive Officer, Director)Steve Kraus(Director)Campbell Murray(Director)Hannes Smarason(Director)Christoph Westphal(Director)
Board seatChristoph WestphalLea Hachigian· per SEC Form D · $23.3M raise · filed Jul 2019
Biotech company that reached IPO
BiotechCambridge
KEVIN LEE(Executive Officer, Director)FELIX J. BAKER(Director)RICHARD N. KENDER(Director)GREGORY WINTER(Director)STEPHEN SANDS(Director)NIGEL CROCKETT(Executive Officer)
GRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Joshua Ofman, MD, MSHS(Chief Executive Officer)Aaron Freidin(Executive Officer)Sarah Krevans(Director)Gregory Summe(Director)Josh Ofman(Executive Officer)Steve Mizell(Director)
BiotechSouth Plainfield, US
Dawn Svoronos(Director)Stuart W. Peltz(Executive Officer, Director)David P. Southwell(Director)Allan S. Jacobson(Director)Mark E. Boulding(Executive Officer)Christine Utter(Executive Officer)
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergTIMOTHY BARBERICH(Director)ALISON LAWTON(Director)ERIC ROWINSKY(Director)BRUCE WENDEL(Director)GINA CONSYLMAN(Director)
HealthtechLowell, US
PJ Anand(Executive Officer, Director)Edgar Jannotta, Jr.(Director)
BoardEdgar D. Jannotta(Director)Norbert Riedel(Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $31.6M raise · filed Jan 2025
BiotechScottsdale, US
Stanton Rowe(Director)Darryl Baker(Executive Officer)Elsa Abruzzo(Executive Officer, Director)Stephen Oesterle(Director)PJ Anand(Director)Ghassan Kassab(Director)
Board seatDavid Donabedian· per SEC Form D · $16.4M raise · filed Nov 2025
HealthtechLexington, US
David Donabedian(Director)Robert Manning(Director)Nada Jain(Director)John Edwards(Director)Henry Kay(Director)Barbara S. Fox(Executive Officer, Director)
Board seatDavid Donabedian· per SEC Form D · $5M raise · filed Jul 2015
BiotechBoston, US
SARKIS K. MAZMANIAN(Director)JAMES C. BLAIR(Director)Ronald C. Renaud Jr.(Director)DAVID H. DONABEDIAN(CHIEF EXECUTIVE OFFICER OF THE ISSUER)MICHELLE DIPP(Director)Henry Wolf(Director)
Board seatRichard P. Aldrich· per SEC Form D · $28M raise · filed Nov 2018
Boston, US
Board seatDavid Steinberg· per SEC Form D · $38M raise · filed Jan 2022
HealthtechCarlsbad, US
Stephen Loomis(Executive Officer)M Bolyard(Director)Brian Dovey(Director)Josh Baltzell(Director)Mary Fisher(Executive Officer, Director)Daniell Turner III(Director)
Board seatRichard Aldrich· per SEC Form D · $4.2M raise · filed Mar 2017
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Laura Brass(Director)Amanda Wagner(Executive Officer)Kai Wucherpfennig(Director)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
Board seatChristoph Westphal· per SEC Form D
HealthtechLunenburg, US
Richard Upton(Director)Edgar D. Jannotta Jr.(Director)Norbert Riedel(Director)David Donabedian(Director)PJ Anand(Executive Officer, Director)Stephen Oesterle(Director)
Board seatDavid Donabedian· per SEC Form D · $21.5M raise · filed May 2026
BiotechBoston, US
David Donabedian(Executive Officer, Director)Robert Hadfield(Executive Officer)John McCabe(Executive Officer)
BoardMing Cheah(Director)Raymond Camahort(Director)
Board seatChristoph Westphal· per SEC Form D · $93.4M raise · filed Feb 2025
Boston, US
Tara Butler(Director)Adam Stone(Director)Jim O'Connor(Executive Officer)Dan Levangie(Director)Eileen Maus(Executive Officer, Director)John Fallon(Director)
Board seatRich Aldrich· per SEC Form D · $19.1M raise · filed Apr 2021
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Bruce Booth(Director)Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Stefan Vitorovic(Director)Evan Thackaberry(Executive Officer)
Board seatShaan C. Gandhi· per SEC Form D · $75M raise · filed Aug 2022
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))Daniel Hicklin(Executive Officer, Director)Alon Lazarus(Director)David Cordo(Executive Officer)Christoph Westphal(Director)
Board seatChristoph Westphal· per SEC Form D
Clinical-stage gene therapy company developing AAV therapeutics for inherited retinal disorders.
HealthtechBoulder, US
Christian LaPointe(Executive Officer)Kyle Lefkoff(Director)Jason Myers(Executive Officer, Director)Paul Manning(Director)
HealthtechEmeryville, US
Dr. Jason Hong(Director)Daniel Burnett(Director)Anthony Natale(Director)Carter Mayer(Director)Ulric Cote(Executive Officer, Director)Andrew Farquharson(Director)
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Aleks Radovic-Moreno(Director)Dmitrij Hristodorov(Director)Dan Janney(Director)Christopher Loose(Executive Officer, Director)Cassidy Blundell(Director)Sanjay Magavi(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Longwood Fund invest at?
- Longwood Fund invests at the Seed, Series A, Series B stages.
- What sectors does Longwood Fund focus on?
- Longwood Fund focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is Longwood Fund located?
- Longwood Fund is headquartered in Boston, US.
- Does Longwood Fund lead rounds?
- Longwood Fund typically participates in rounds rather than leading them.
Images
Co-investors · 15
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Alta Partners is a venture capital firm focused on the healthcare and life sciences sector, backing entrepreneurs building companies across biotechnology, therapeutics, and healthcare innovation.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Aisling Capital is an investment firm focused on companies developing and commercializing innovative healthcare products, services, and technologies.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.
.jpeg){kind=logo}
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
▶3 more co-investors
Longitude CapitalWestlake Village BioPartnersDe Novo Ventures
Firms observed investing alongside Longwood Fund, from public investor directories. Shared companies are the overlap with Longwood Fund's recorded portfolio.
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
Seventure Partners is a European venture capital firm investing across life sciences, digital technologies, sport and performance, and the blue economy.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Truffle Capital is an independent European venture firm that creates, finances, and develops technology companies in Life Sciences (MedTech and Biotech) and Deeptech applied to finance (Fintech and Insurtech).